{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:20:46Z","timestamp":1790713246025,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS Emerging Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014846","name":"Pasteur Mutuality Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014846","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.idnow.2025.105040","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T03:48:57Z","timestamp":1739677737000},"page":"105040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV"],"prefix":"10.1016","volume":"55","author":[{"given":"Vincent","family":"Guiraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Sauce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Bittar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Th\u00e9venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Teyssou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Alkouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bonnefont-Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2025.105040_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors\u2014Perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"issue":"17","key":"10.1016\/j.idnow.2025.105040_b0010","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.idnow.2025.105040_b0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.idnow.2025.105040_b0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.humimm.2021.03.004","article-title":"Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy","volume":"82","author":"Borzouei","year":"2021","journal-title":"Hum Immunol"},{"issue":"10","key":"10.1016\/j.idnow.2025.105040_b0025","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.idnow.2025.105040_b0030","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","volume":"35","author":"Jenkins","year":"2023","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.idnow.2025.105040_b0035","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.idnow.2025.105040_b0040","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: Systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.idnow.2025.105040_b0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95726","article-title":"Reevaluation of immune activation in the era of cART and an aging HIV-infected population","volume":"2","author":"De Armas","year":"2017","journal-title":"JCI Insight"},{"issue":"16","key":"10.1016\/j.idnow.2025.105040_b0050","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.idnow.2025.105040_b0055","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.idnow.2025.105040_b0060","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: A randomized, placebo\u2010controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"JAHA"},{"issue":"12","key":"10.1016\/j.idnow.2025.105040_b0065","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/dom.14517","article-title":"Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo\u2010controlled study","volume":"23","author":"Thiele","year":"2021","journal-title":"Diabetes Obesity Metabolism"},{"issue":"10","key":"10.1016\/j.idnow.2025.105040_b0070","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.idnow.2025.105040_b0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.idnow.2025.105040_b0080","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/ehf2.13615","article-title":"Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA\u2010REG OUTCOME trial","volume":"8","author":"Fitchett","year":"2021","journal-title":"ESC Heart Failure"},{"issue":"1","key":"10.1016\/j.idnow.2025.105040_b0085","first-page":"57","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC","volume":"8","author":"Li","year":"2020","journal-title":"Heart Failure"},{"issue":"8","key":"10.1016\/j.idnow.2025.105040_b0090","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.idnow.2025.105040_b0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.idnow.2025.105040_b0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"Van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.idnow.2025.105040_b0105","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"JASN"},{"issue":"1","key":"10.1016\/j.idnow.2025.105040_b0110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13098-022-00951-5","article-title":"The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial","volume":"14","author":"Gohari","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.idnow.2025.105040_b0115","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J"},{"key":"10.1016\/j.idnow.2025.105040_b0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fcvm.2020.00095","article-title":"NLRP3 Inflammasome signaling as a link between HIV-1 infection and atherosclerotic cardiovascular disease","volume":"7","author":"Mullis","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.idnow.2025.105040_b0125","article-title":"Coronary artery plaque composition and severity relate to the inflammasome in people with treated human immunodeficiency virus","volume":"10(3):ofad106","author":"Schnittman","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idnow.2025.105040_b0130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"issue":"21","key":"10.1016\/j.idnow.2025.105040_b0135","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.3390\/ijms21218189","article-title":"Empagliflozin inhibits basal and IL-1\u03b2-mediated MCP-1\/CCL2 and endothelin-1 expression in human proximal tubular cells","volume":"21","author":"Pirklbauer","year":"2020","journal-title":"IJMS"},{"issue":"1","key":"10.1016\/j.idnow.2025.105040_b0140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.idnow.2025.105040_b0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.idnow.2025.105040_b0150","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/dom.14779","article-title":"Mechanisms of action of the sodium\u2010glucose cotransporter\u20102 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial","volume":"24","author":"Sen","year":"2022","journal-title":"Diabetes Obesity Metabolism"},{"issue":"6","key":"10.1016\/j.idnow.2025.105040_b0155","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.idnow.2025.105040_b0160","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri3070","article-title":"Monocyte recruitment during infection and inflammation","volume":"11","author":"Shi","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.idnow.2025.105040_b0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.idnow.2025.105040_b0170","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1365-2567.1997.00263.x","article-title":"Interleukin\u201013 selectively induces monocyte chemoattractant protein\u20101 synthesis and secretion by human endothelial cells. Involvement of IL\u20104R \u03b1 and Stat6 phosphorylation","volume":"91","author":"Goebeler","year":"1997","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.idnow.2025.105040_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065182","article-title":"Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. Unutmaz D, \u00e9diteur","volume":"8","author":"R\u00f6nsholt","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.idnow.2025.105040_b0180","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac208","article-title":"Association between inflammation and coagulation biomarkers and carotid atherosclerosis among treated people with human immunodeficiency virus","volume":"9","author":"Zhu","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idnow.2025.105040_b0185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/cid\/ciac767","article-title":"Sex differences in subclinical atherosclerosis and systemic immune activation\/inflammation among people with human immunodeficiency virus in the united states","volume":"76","author":"Zanni","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2025.105040_b0190","doi-asserted-by":"crossref","unstructured":"on behalf of the SUMMIT Investigators, Looker HC, Colombo M, Agakov F, Zeller T, Groop L, et al. Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia. 2015;58(6):1363\u201171.","DOI":"10.1007\/s00125-015-3535-6"},{"issue":"9","key":"10.1016\/j.idnow.2025.105040_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008885","article-title":"CX3CL1 and IL-15 promote CD8 T cell chemoattraction in HIV and in atherosclerosis. Douek DC, \u00e9diteur","volume":"16","author":"Panigrahi","year":"2020","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.idnow.2025.105040_b0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/QAI.0000000000003227","article-title":"Brief report: Use and side effects of sodium-glucose transporter 2 inhibitors among us people with HIV with clinical indications","volume":"94","author":"Sise","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.idnow.2025.105040_b0205","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1071\/SH22070","article-title":"Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV. Fairley C, \u00e9diteur","volume":"19","author":"Butale","year":"2022","journal-title":"Sex Health"},{"key":"10.1016\/j.idnow.2025.105040_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103129","article-title":"Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection","volume":"62","author":"Novelli","year":"2020","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.idnow.2025.105040_b0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cyto.2011.06.012","article-title":"Intra-individual variability over time in serum cytokine levels among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","volume":"56","author":"Hofmann","year":"2011","journal-title":"Cytokine"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:35:51Z","timestamp":1741700151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925000193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666991925000193"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105040","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105040"}}